Related Experiment Video
Updated: May 11, 2026
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Biomarkers and correlative endpoints for immunotherapy trials
Michael A Morse1, Takuya Osada, Amy Hobeika
1From the Duke University Medical Center, Durham, NC.
Summary
Developing effective lung cancer immunotherapies requires identifying predictive biomarkers. Multiple biomarkers, including tissue and blood markers, are crucial for guiding treatment and predicting patient benefit in clinical trials.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Lung cancer immunotherapies are advancing to Phase III trials.
- Identifying predictive biomarkers is critical for treatment success and patient selection.
Purpose of the Study:
- To highlight the need for multiple biomarkers to guide lung cancer immunotherapy development.
- To discuss the importance of both peripheral blood and tumor tissue analysis.
- To explore the development of intermediary clinical endpoints.
Main Methods:
- Review of current immunotherapy research and biomarker strategies.
- Discussion of peripheral blood assays (ELISPOT, cytokine flow cytometry).
- Emphasis on the necessity of tumor tissue analysis for immune response characterization.
Main Results:
- Current peripheral blood markers are standard but insufficient alone.
- Tumor microenvironment analysis is increasingly vital.
- Early clinical endpoints may not correlate with overall survival for immunotherapies.
Conclusions:
- Multiple biomarkers are essential for comprehensive assessment of lung cancer immunotherapy efficacy.
- Developing novel intermediary clinical endpoints is necessary.
- Findings in other malignancies may inform lung cancer immunotherapy biomarker strategies.
